

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Johannes Bonenberger

Serial No.: 10/529,700

Filed: April 7, 2006

For: METHOD FOR DETECTING ANALYTES

Group Art Unit: 1641

Examiner: Diramio, Jacqueline A.

Atty. Dkt. No.: DEBE:056US

**CERTIFICATE OF ELECTRONIC SUBMISSION**

DATE OF SUBMISSION: August 7, 2006

**INFORMATION DISCLOSURE STATEMENT**

**MS AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Sir:


In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/DEBE:056US.

Applicant respectfully requests that the listed documents be made of record in the present case.

Respectfully submitted,



Steven J. Highlander  
Reg. No. 37,642  
Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P.  
600 Congress Avenue, Suite 2400  
Austin, Texas 78701  
(512) 474-5201

Date: August 7, 2006

Form PTO-1449 (modified)	Atty. Docket No. <b>DEBE:056US</b>	Serial No. <b>10/529,700</b>
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicant <b>Johannes Bonenberger</b>	
	Filing Date: <b>April 7, 2006</b>	Group: <b>1641</b>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>

### U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2002/0001853	01/03/02	Obremski <i>et al.</i>	436	518	04/21/98
	A2	5,516,635	05/14/96	Ekins <i>et al.</i>	435	6	10/15/92

### Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	EP 0 811 842	12/10/97	Europe			Abstract
	B2	WO 95/15981	06/15/95	WIPO			English

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Borchelt <i>et al.</i> , "A vector for expressing foreign genes in the brains and hearts of transgenic mice," <i>Genetic Analysis: Biomolecular Engineering</i> , 13:159-163, 1996.
	C2	Borchelt <i>et al.</i> , "Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins," <i>Neuron</i> , 19:939-945, 1997.
	C3	Borchelt <i>et al.</i> , "Familial Alzheimer's disease-linked presenilin 1 variants elevated A $\beta$ 1-42/1-40 ratio in vitro and invivo," <i>Neuron</i> , 17:1005-1013, 1996.
	C4	De Stropper <i>et al.</i> , "Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein," <i>Nature</i> , 391:387-713, 1998.
	C5	Duff <i>et al.</i> , "Increased amyloid- $\beta$ 42(43) in brains of mice expressing mutant presenilin 1," <i>Nature</i> , 383:710-713, 1996.
	C6	Edbauer <i>et al.</i> , "Reconstitution of $\gamma$ -secretase activity," <i>Nature Cell Biology</i> , 1(5):486-488, 2003.
	C7	Evin <i>et al.</i> , "Presenilin I expression in yeast lowers secretion of the amyloid precursor protein," <i>Molecular Neuroscience</i> , 11(2):405-408, 2000.

25537781.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. <b>DEBE:056US</b>	Serial No. <b>10/529,700</b>
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)	Applicant <b>Johannes Bonenberger</b>	
	Filing Date: <b>April 7, 2006</b>	Group: <b>1641</b>
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 1</i>	Other Art <i>See Page 1</i>

### Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C8	Holcomb <i>et al.</i> , "Accelerated alzheimer-type phenotype in transgenic mice carrying both mutant <i>amyloid precursor protein</i> and <i>presenilin 1</i> transgenes," <i>Nature Medicine</i> , 14:97-100, 1998.
	C9	Iwatsubo <i>et al.</i> , "Visualization of A $\beta$ 42(43) and A $\beta$ 40 in senile plaques with end-specific A $\beta$ monoclonals: evidence that an initially deposited species is A $\beta$ 42(43)," <i>Neuron</i> , 13:45-53, 1994.
	C10	Jarrett <i>et al.</i> , The C-Terminus of the $\beta$ protein is critical in amyloidogenesis," <i>Annals NY Academy of Sciences</i> , 144-148,
	C11	Li <i>et al.</i> , Photoactivated $\gamma$ -secretase inhibitors directed to the active site covalently label presenilin 1," <i>Nature</i> , 405:689-693, 2000.
	C12	Nakamura <i>et al.</i> , "Enzyme immunoassays: heterogeneous and homogeneous systems," In: <i>Handbook of Experimental Immunology</i> (4 <sup>th</sup> Ed), Weir <i>et al.</i> , (eds)1:27.1-27.20.
	C13	Naruse <i>et al.</i> , "Effects of PS1 deficiency on membrane protein trafficking in neurons," <i>Neuron</i> , 21:1213-1221, 1998.
	C14	Roia, F., "Immunizing agents and diagnostic skin antigens," In: <i>Remington's Pharmaceutical Sciences</i> , 18 <sup>th</sup> Ed. Mack Printing Co., 1389-1404, 1990.
	C15	Scheuner <i>et al.</i> , "Secreted amyloid $\beta$ -protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease," <i>Nature Medicine</i> , 2(8):964-870, 1996.
	C16	Sears <i>et al.</i> , A versatile set of vectors for constitutive and regulated gene expression in <i>Pichia pastoris</i> ," <i>Yeast</i> , 14:783-790, 1998.
	C17	Sisodia <i>et al.</i> , Function and dysfunction of the presenilins," <i>Am. J. Hum. Genet.</i> 65:7-12, 1999.
	C18	Tomita <i>et al.</i> , The presenilin 2 mutation (N1411) linked to familial Alzheimer disease (Volga German families) increases the secretion of amyloid $\beta$ protein ending at the 42 <sup>nd</sup> (or 43 <sup>rd</sup> ) residue," <i>Proc. Natl. Acad. Sci. USA</i> , 94:2025-2030, 1997.
	C19	Uhlén <i>et al.</i> , " $\alpha$ -Haemolysin of uropathogenic <i>E. coli</i> induces CA <sup>2+</sup> oscillations in renal epithelial cells," <i>Letters to Nature</i> , 405:694, 2000.
	C20	Wolfe <i>et al.</i> , "Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and $\gamma$ -secretase activity," <i>Nature</i> , 398:513517, 1999.

25537781.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.